HIND (Vyome Holdings) Total Operating Expense: $3.76 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HIND Vyome Holdings Inc HIND
11 GF Score
Price $2.07
! 2 Warning Signs
View Full Analysis

What is Vyome Holdings Total Operating Expense?

Vyome Holdings HIND +4.02% 11 Total Operating Expense is $3.76 Mil as of Mar. 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Vyome Holdings's Total Operating Expense for the three months ended in Mar. 2026 was $1.15 Mil. Vyome Holdings's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $3.76 Mil.

Vyome Holdings Total Operating Expense Related Terms

Vyome Holdings Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Vyome Holdings's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vyome Holdings Total Operating Expense Chart

Vyome Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
1.25 1.05 1.20 2.97

Vyome Holdings Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.35 0.89 1.38 1.15
HIND
11GF Score
Vyome Holdings Inc HIND
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vyome Holdings Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $3.76 Mil mean?
Vyome Holdings (HIND) has a Total Operating Expense of $3.76 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Vyome Holdings and its competitors.
Is Vyome Holdings' Total Operating Expense too high?
Vyome Holdings' current Total Operating Expense is $3.76 Mil. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Total Operating Expense compare to CTXR and MBRX?
Vyome Holdings' Total Operating Expense of $3.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current Total Operating Expense is $3.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Total Operating Expense of $3.76 Mil. The current Total Operating Expense is $3.76 Mil. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Total Operating Expense is $3.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vyome Holdings Business Description

Address Harvard Square, Suite 400, One Mifflin Place, Cambridge, MA, USA, 02138
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score

Get the complete analysis for HIND

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price